Roberto Stasi1. 1. Regina Apostolorum Hospital, Department of Medical Sciences, Via S. Francesco, 50, 00041 Albano Laziale, Italy. roberto.stasi@uniroma2.it
Abstract
BACKGROUND: Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody. OBJECTIVES: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia. METHODS: Review and summary of publications on gemtuzumab ozogamicin indexed in the PubMed electronic database. RESULTS/ CONCLUSIONS: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia. The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation. Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
BACKGROUND:Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody. OBJECTIVES: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia. METHODS: Review and summary of publications on gemtuzumab ozogamicin indexed in the PubMed electronic database. RESULTS/ CONCLUSIONS:Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia. The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation. Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
Authors: Ingo Schubert; Christian Kellner; Christoph Stein; Markus Kügler; Michael Schwenkert; Domenica Saul; Kristin Mentz; Heiko Singer; Bernhard Stockmeyer; Wolfgang Hillen; Andreas Mackensen; Georg H Fey Journal: MAbs Date: 2011-01-01 Impact factor: 5.857
Authors: A Dutour; V Marin; I Pizzitola; S Valsesia-Wittmann; D Lee; E Yvon; H Finney; A Lawson; M Brenner; A Biondi; E Biagi; R Rousseau Journal: Adv Hematol Date: 2012-01-05